Published online Jul 28, 2021. doi: 10.4329/wjr.v13.i7.223
Peer-review started: March 15, 2021
First decision: April 6, 2021
Revised: April 10, 2021
Accepted: June 18, 2021
Article in press: June 18, 2021
Published online: July 28, 2021
Multiple myeloma (MM) is the second most common type of hematological disease with its incidence rising in the elderly. In MM, the extent of the bone disease increases both morbidity and mortality. The detection of lytic bone lesions on imaging, especially computerized tomography (CT) and magnetic resonance imaging (MRI) is crucial to separate asymptomatic from symptomatic MM patients even when no clinical symptoms are present. Although radiology is essential in the staging and management of patients with MM there is still high variability in the choice between MRI and CT. In addition, there is still suboptimal agreement among readers. The potential of medical imaging in MM is largely under-evaluated: artificial intelligence, radiomics and new quantitative methods to report CT and MRI will improve imaging usage.
Core Tip: Introduction of new quantitative scores and biomarkers to predict multiple myeloma (MM) prognosis, possibly outperforming current staging methods to create new reliable standards for disease prediction and monitoring is an opportunity for further research in MM imaging.